Kezar Net Income From Continuing Ops from 2010 to 2026

KZR Stock

USD 6.85 -0.33 -4.60%

Kezar Life's Net Loss is decreasing over recent years with slightly volatile volatility. It is projected to reach approximately -71.6 M this year. From 2010 to 2026, Kezar Life Net Loss regression analysis produced a r-value of -0.91 . and median of -23,167,000 . View All Fundamentals

Net Loss

First Reported

2016-12-31

Previous Quarter

-13.7 M

Current Value

-11.2 M

Quarterly Volatility

7.4 M

Macro event markers

Covid

Interest Hikes

Review Kezar Life financial statements over time to add context on performance and capital structure. Key drivers include Net Interest Income of 8.3 M, Interest Income of 10.2 M or Depreciation And Amortization of 1 M along with ratios such as Price To Sales Ratio of 785, Dividend Yield of 0.0 or PTB Ratio of 3.96. This view complements Kezar Life Valuation and Volatility modules.

Build AI portfolio with Kezar Stock

Review Kezar Life Correlation against competitors for Kezar Life. This adds peer-relative context.

Evaluating Kezar Life's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Kezar Life Sciences's fundamental strength.

Latest Kezar Life's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Kezar Life Sciences over the last few years. It is Kezar Life's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kezar Life's overall financial position and show how it may be relating to other accounts over time.

Net Income From Continuing Ops

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Income From Continuing Ops

Timeline

Kezar Net Income From Continuing Ops Regression Statistics

	Arithmetic Mean	-36,046,805
	Coefficient Of Variation	-85.57
	Mean Deviation	27,149,064
	Median	-23,167,000
	Standard Deviation	30,846,762
	Sample Variance	951.5T
	Range	79.3M
	R-Value	-0.91
	Mean Square Error	170.1T
	R-Squared	0.83
	Slope	-5,573,314
	Total Sum of Squares	15224.4T

Kezar Net Income From Continuing Ops History

	2026	-71.6 M
	2025	-75.4 M
	2024	-83.7 M
	2023	-87.8 M
	2022	-68.2 M
	2021	-54.6 M
	2020	-41.7 M

Stock Overview, Methodology & Data Sources

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company was incorporated in 2015 and is based in South San Francisco, California. Kezar Life operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. The stock overview for Kezar Life summarizes business drivers, financial profile, and market behavior. The company is positioned within Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/B of 0.62. Kezar Life has a market cap of 52.58 M, ROE of -56.86%.

Methodology

Unless otherwise specified, financial data for Kezar Life Sciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Kezar (USA Stocks:KZR) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Kezar Life Sciences is covered by 3 analysts. 1 analyst has submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Oppenheimer & Co., Jefferies, Stifel, BMO Capital Markets, HSBC Global Research, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Vlad Skutelnik - Macroaxis Contributor

Pair Trading with Kezar Life

Pair trading with Kezar Life can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.

Moving against Kezar Stock

0.39	IVVD	Invivyd	Pair Corr
0.34	CRDF	Cardiff Oncology	Pair Corr

The ability to find closely correlated positions to Kezar Life could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kezar Life when you sell it.

The correlation of Kezar Life is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1.

Correlation analysis and pair trading evaluation for Kezar Life can be used to frame hedging context. The approach can be applied within sectors or across broader universes.

Pair Correlation Correlation Matching

Additional Tools for Kezar Stock Analysis

	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC